Abstract. Thyrotropin releasing hormone receptor 1 (TRHR1) and 2 (TRHR2) mRNAs were examined using reverse transcription polymerase chain reaction (RT-PCR). These data were then correlated with endocrinological and histological characteristics in 65 human pituitary adenomas including one non tumorous pituitary gland, to clarify the role of TRHR1 and 2 gene expression in human pituitary adenomas, especially as it relates to the paradoxical stimulatory effects of TRH found in pituitary adenomas. TRHR mRNA was not identified in four ACTH cell adenomas, whereas TRHR mRNA expression was found in 12/23 acromegaly specimens, 7/8 prolactinomas, 3/3 TSH cell adenomas, and 22/27 clinically nonfunctioning adenomas. Specimens obtained from patients expressing the TRHR gene were found to express TRHR1 and TRHR2 or TRHR1 alone, whereas no cases were identified in which TRHR2 alone was expressed. In examining the relationship between GH, PRL, TSH, or gonadotropin subunit response to TRH administration and TRHR gene expression, TRHR mRNA was found to be absent in 9 out of 10 GH cell adenomas without paradoxical GH response to TRH (non-responder), whereas TRHR genes were shown to be expressed in 10 out of 12 GH cell adenomas with paradoxical GH response to TRH (responders) (c 2 = 11.73, p = 0.0009). However, there was no significant correlation between TRHR gene expression and responsiveness to PRL or gonadotropins to TRH administration in PRL cell adenomas (c 2 = 0.16, p = 0.87) or gonadotroph cell adenomas (c 2 = 0.0006, p = 1), respectively. We concluded that the existence of the TRH receptor in adenoma cells plays an important role in the paradoxical GH response to TRH administration in GH cell adenomas. It should be noted that the PRL response to TRH in prolactinoma or an abnormal response of gonadotropin and/or its subunits to TRH in gonadotroph cell adenomas is considered to be due to a mechanism other than direct TRH action in adenoma cells. However, further studies are required to elucidate the role of TRHR2 in pituitary adenomas.
THYROTROPIN releasing hormone (TRH) stimulates the release of TSH and PRL from the pituitary gland under physiological conditions. In contrast, the paradoxical stimulatory effect of TRH on GH secretion or on gonadotropin subunits expression is often associated with acromegaly or gonadotroph cell adenomas, respectively [1, 2] , while PRL responses to TRH administration in prolactinoma are usually reduced [3] . Indeed, a variety of abnormal hormone responses to TRH have been reported in patients with pituitary adenomas, but little is known about the mechanism of these abnormal responses to TRH in pituitary adenomas. Moreover, results of the relationship between TRH receptor (TRHR) gene expression and abnormal hormone responses to TRH in pituitary adenomas are not consistent among investigators [4] [5] [6] .
Recently, a novel short form of human TRHR (termed TRHR2) mRNA in normal or tumorous pituitary has been identified, which can be produced by alternative splicing at the internal acceptor site of exon 3 [5] . TRHR2 lacks the sixth and seventh transmembrane domains, and cannot bind to [ 3 H]Me TRH itself [5] . The mRNA ratio of TRHR2 versus the wildtype TRHR1 has been reported to be significantly different among pituitary adenomas, suggesting that TRHR2 mRNA may alter the cellular responsiveness to TRH by affecting the degradation rate of TRHR1 mRNA [5] . However, the question still remains regarding the functional role of TRHR2 gene expression in pituitary adenomas.
In the present study, we examined TRHR1 and 2 gene expression in a large number of human pituitary adenomas using reverse transcription polymerase chain reaction (RT-PCR) and then correlated these data with endocrinological and histological characteristics in these adenomas to clarify the role of TRHR1 and 2 gene expression in human pituitary adenomas.
Materials and Methods

Patients
Dynamic hormone studies following TRH administration (500 mg intravenously) were performed preoperatively and hormone levels (in addition to TSH and PRL in each adenoma, GH or a-subunit, LH, and FSH in acromegaly or gonadotroph cell adenomas, ACTH in Cushing's disease, respectively) were measured in blood samples drawn 0, 30, 60, 90, and 120 minutes after administration, and responses to TRH were judged as abnormal or stimulated when plasma hormone levels rose by 50% or more over basal concentrations [7, 8] .
Pituitary adenoma tissues were obtained during transsphenoidal surgery from 65 patients including 23 acromegaly, 8 prolactinomas, 3 TSH cell adenomas, 4 ACTH cell adenomas, and 27 clinically nonfunctioning adenomas. Tissues were prepared for pathological diagnosis and fresh tumor tissue was immediately snap-frozen in liquid nitrogen and stored at -80°C until used for extraction of RNA. In addition, one non-tumorous human pituitary obtained at autopsy was also studied as control. This study was approved by the institutional review board at Toranomon Hospital and Okinaka Memorial Institute for Medical Research, Japan.
Histological studies
For light microscopy, tissues were fixed in 10% buffered formalin and embedded in paraffin. Sections of 4-6 mm thickness were stained by haematoxylineosin. Immunohistochemistry was performed by the avidin-biotin-peroxidase complex method using an ABC kit (Vector laboratories Inc. Burlingame, USA) on formalin-fixed paraffin-embedded tissue with the following antibodies: polyclonal antiserum to GH (Dakopatts, Glostrup, Denmark, diluted 1:800) and ACTH (Dakopatts, 1:1600), and monoclonal antibodies to PRL (Immunotech, Marseille, France, 1:100), the b-subunit of TSH (TSHb) (Chemicon, Temecula, USA, 1:100), the b-subunit of FSH (FSHb) (Immunotech, 1:100), the b-subunit of LH (LHb) (Immunotech, 1:100) and the a-subunit of glycoprotein hormone (INC Immuno-Biological, Lisle, USA, 1:1000). The specificity of immunostaining was confirmed using appropriate controls including nonimmune rabbit serum and mouse IgG, as well as antiserum preabsorbed with the corresponding antigens.
Complementary DNA (cDNA) synthesis Total RNA was isolated and purified from each sample using a nucleic acid separation kit, ISOGEN (Nippon Gene, Tokyo, Japan). Reverse transcription was performed by incubating 1 mg total RNA with 1 ml of PowerScript reverse transcriptase (Clontech, USA) and 1 ml of 0.5 mg/ml oligo(dT) [12] [13] [14] [15] [16] [17] [18] primer (Life Technologies, USA) at 42°C for 70 minutes in 20 ml reaction buffer. RT products were diluted ten times with 10 mM Tricine-KOH (pH 9.2)/0.1 mM EDTA, and stored at -20°C until used for PCR.
Polymerase chain reaction (PCR)
PCR primers for TRHR were designed based on the human TRHR mRNA sequence [9] . Primer sequences used for PCR were as follows: F3 (sense), 5'-ggctacaagatctccaggaattactac-3'; R2 (antisense), 5'-gttctcccttttgttgatgactgcac-3', F2 (sense), 5'-agatgtttcaacagcacagtatcttc-3'; R3 (antisense), 5'-cacactgtagttagcaggtttctctgt-3'. Sense and antisense primers are derived from exons 2 and 3 of the human TRHR gene, respectively. The resulting product from TRHR1 (297 bp) or TRHR2 (169 bp) cDNA is distinguished from the corresponding region (25 kb) of the gene.
PCR was carried out in a solution containing 0.2 ml of 50× Titanium Taq DNA polymerase (Clontech, USA), 1 ml of 10× Titanium Taq PCR buffer, 0.1 ml of 50 mM F3 and R2 primers, 0.2 ml of dNTPs (10 mM each of dATP, dCTP, dGTP, dTTP) and 6.4 ml of SDW using the GeneAmp PCR system 9700 (Perkin Elmer Applied Biosystems). RT products (2 ml) were diluted in 10 ml per PCR reaction mixture. Following denaturation of the first-strand cDNA at 95°C for 1 min, PCR was performed using F3 and R2 primers with 30 cycles amplification according to the following profile: denaturation at 95°C for 30 seconds, annealing/extension at 68°C for 1 min, followed by a final extension step at 68°C for 3 min.
Following PCR, the target sequence was subjected to "nested PCR" using an inner primer set (F2 and R3). The PCR reaction mixture from the first PCR was diluted 100 times with 10 mM Tricine-KOH (pH 9.2) /0.1 mM EDTA, and then 2 ml of the dilution was used as template in the second PCR (final volume, 10 ml). Nested PCR was performed with the same conditions as that of the first PCR except that the annealing /extension time was shortened to 40 seconds.
To confirm the integrity of RNA for each sample, mRNA for the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene, a housekeeping gene, was detected by RT-PCR using gene specific primers for human GAPDH (Stratagene, USA). The amplified PCR product for GAPDH, a fragment spanning between exons 4 and 8, was confirmed to be 594 bps. PCR was performed according to the following thermal profile: 30 cycles of denaturation at 95°C for 30 seconds, and annealing/extension at 68°C for 1 min, followed by a final extension step at 68°C for 3 min. PCR products were subjected to electrophoresis in a 3% agarose gel (LO3, Takara, Japan) stained with ethidium bromide and visualized under UV light.
Statistical analysis
All results were compared using a Fisher's exact probability test. A p-value <0.05 was considered to be significant.
Results
Tumor characterization
Clinical, endocrinological, and pathological data in all 65 pituitary adenomas examined in this study are summarized in Table 1 .
Expression of TRHR mRNA
PCR for GAPDH showed intact RNA for all samples. Only one band corresponding to TRHR1 mRNA was recognized in one normal human pituitary, whereas two distinct bands corresponding to TRHR1 and TRHR2 mRNA were differentiated in some pituitary adenomas ( Fig. 1) .
TRHR mRNA was not detected in four ACTH cell adenomas (plasma ACTH did not respond to TRH in two of the examined patients), whereas TRHR mRNA expression was shown to be expressed in 12/23 acromegaly specimens, 7/8 prolactinomas, 3/3 TSH cell adenomas, and 22/27 clinically nonfunctioning adenomas. In patients expressing the TRHR gene, both TRHR1 and TRHR2 mRNA were shown to be expressed in 1/12 acromegaly specimens, 1/7 prolactinomas, 1/3 TSH cell adenomas and 13/22 clinically nonfunctioning adenomas, whereas TRHR1 mRNA alone was found in 11/12 acromegaly specimens, 6/7 prolactinomas, 2/3 TSH cell adenomas and 9/22 clinically nonfunctioning adenomas. These findings appear to suggest that both types of mRNA were more frequently expressed in clinically nonfunctioning adenoma, whereas TRHR1 mRNA alone was found more commonly in GH, PRL and TSH cell adenomas. In contrast, there were no cases expressing TRHR2 mRNA alone (Fig. 2) . The expression of TRHR1 mRNA alone or both TRHR1 and TRHR2 mRNA was significantly different between GH cell adenomas (c 2 = 8.25, p = 0.004) or prolactinomas (c 2 = 4.26, p = 0.049) and clinically nonfunctioning adenomas.
These adenomas are histologically diagnosesd based on immunohistochemical findings. Twentythree acromegalic patients were histologically subtyped into 17 densely, five sparse, and one GH and PRL cell adenoma. Similarly, 27 clinically nonfunc-tioning adenomas were histologically classified into 21 gonadotroph cell adenomas, five null cell adenomas, and one silent corticotroph cell adenoma. When TRHR gene expression was correlated with histological subtypes in acromegaly and clinically nonfunctioning adenomas, neither TRHR1 or TRHR2 mRNAs were detected in four out of five sparsely granulated GH cell adenomas. In contrast, six out of 17 densely granulated cases were found not to express TRHR mRNA, suggesting a more frequent TRHR gene expression in densely GH cell adenomas compared to sparsely types, although it was found to be not significantly different (c 2 = 2.75, p = 0.12). Moreover, like functioning ACTH cell adenoma, TRHR mRNA was not detected in one silent corticotroph cell adenoma. However, there were no definite differences between gonadotroph cell adenomas and null cell adenomas with respect to TRHR gene expression (c 2 = 2.88, p = 0.154).
The relationship between GH, PRL, TSH, or subunits of gonadotropin response to TRH administration and TRHR gene expression was assessed in acromega- ly specimens, prolactinomas, TSH cell adenomas, and gonadotroph cell adenomas, respectively. TRHR mRNA expressions was absent in 9 out of 10 GH cell adenomas without paradoxical GH response to TRH (non-responder), whereas TRHR genes were shown to be expressed in 10 out of 12 GH cell adenomas with paradoxical GH response to TRH (responders), suggesting that TRHR gene expression was significantly more common in responder than in non-responders in GH cell adenomas (c 2 = 11.73, p = 0.0009). TRHR mRNA was found to be expressed in all TSH cell adenomas, although TSH did not respond to TRH in one patient. There was no significant correlation between TRHR gene expression and responsiveness of PRL or gonadotropins to TRH administration in PRL cell adenomas (c 2 = 0.16, p = 0.87) or gonadotroph cell adenomas (c 2 = 0.0006, p = 1), respectively. In addition, TRHR mRNA expression was significantly more common in males (21/23) compared to females (23/42) (c 2 = 3.84, p = 0.002), although the reasons for this male predisposition are, at present, unknown. In contrast, there was no significant cor- 
Discussion
It has been speculated that TRHR, which belongs to a family of G protein-coupled receptors containing putative seven transmembrane domains, may be involved in the pathogenesis of pituitary tumors. Although a new TRHR gene transcript has been found in some pituitary adenomas [5] , somatic mutations in the TRHR gene have not yet been identified [10, 11] . Both TRH binding and TRHR mRNA have been examined in pituitary adenomas TRHR gene expression has also been identified in various types of adenomas [4-6, 10, 12, 13] . This is the first report investigating the gene expression of both types of TRHR mRNA (TRHR1 and TRHR2) in a large number of patients with various types of pituitary adenoma. The present study clearly confirmed the expression of TRHR mRNA in many pituitary adenomas examined other than ACTH cell adenomas. Regarding TRHR mRNA expression in ACTH cell adenomas, only one case has been studied in the literature to date [4] , and in this patient low levels of TRHR mRNA were detected by competitive quantitative RT-PCR. However, no TRHR gene expression was identified in any of the five ACTH cell adenomas in our study, including one silent type adenoma. In addition, plasma ACTH did not respond to TRH in two of the examined patients. Ujihara et al. reported that in a patient who had Cushing's syndrome, TRH and CRH had no effect on the secretion of ACTH, whereas GnRH increased plasma ACTH levels [14] . Including this report, it is therefore possible to speculate that no response of ACTH to TRH may be due to the lack of TRH receptors in ACTH cell adenoma. Several contrary findings have been reported, with respect to the relationship between TRHR gene expression and abnormal hormone responses to TRH in pituitary adenomas. TRHR mRNA has been identified not only in the paradoxical GH responder to TRH but also in the non-responder [4, 5] , suggesting that GH abnormal response to TRH in acromegaly is owing to a mechanism other than direct TRH action in adenoma cells. By contrast, Kim et al. have claimed that there is a significant and positive correlation between the responsiveness for GH to TRH and the level of TRHR1 mRNA expression in 14 GH-producing adenomas [6] . Among the 23 patients with acromegaly examined in the present study, other than one patient who was not tested to hormonal response to TRH administration, TRHR gene expression was detected in 10 out of 12 responders, whereas it was not detected in 9 out of 10 non-responders. Thus, these findings have confirmed that the existence of the TRH receptor in adenoma cells plays an important role in the paradoxical GH response to TRH administration. Moreover, TRHR mRNA was more frequently shown to be expressed in densely granulated GH cell adenomas than in sparsely granulated GH cell adenomas, although it was found to be not significantly different. This may be due to the finding that the abnormal response of GH to TRH is significantly less common in patients with sparsely granulated GH cell adenomas than densely granulated GH cell adenomas [15] .
Previous studies have reported that two-thirds of TSH cell adenomas demonstrate no TSH response to TRH administration and no TRH binding sites have been confirmed by a radioligand binding study in TSH cell adenomas without a TSH response to TRH [16, 17] . In contrast, TRHR mRNA was found to be expressed in all TSH cell adenomas in our study. However, TSH did not respond to TRH in one patient, suggesting that the TSH response to TRH may also depend on TRHR.
PRL responses to TRH administration are usually reduced in prolactinoma [3] . In the present study, no significant increase of PRL to TRH was found in 7 out of 8 patients. TRHR mRNA was detected in 7 patients, whereas it was not demonstrated in the remaining one patient in whom PRL responded 1.7 times the basal value of TRH. As with previous investigators [4] [5] [6] , the present study has confirmed that no significant correlation was observed between PRL response to TRH and TRHR gene expression. The mechanism explaining the poor PRL response to TRH in prolactinoma despite the expression of TRHR gene still remains unclear.
Approximately 25-30% of patients with pituitary adenomas have no clinical or biochemical evidence of hormone excess, which are classified as "clinically nonfunctioning pituitary adenomas" [18] . These tumors are morphologically heterogeneous and include a gonadotroph cell adenoma, a null cell adenoma, an oncocytoma, and rarely, a nonsecreting cell type usually associated with hormonal hypersecretion (such as a silent corticotroph cell, somatotroph cell, or thyrotroph cell adenoma) [19, 20] . Of the 27 patients examined in this study, other than one patient who was diagnosed with a silent corticotroph cell adenoma, 21 were diagnosed with a gonadotroph cell adenoma and 5 were found to have a null cell adenoma. TRHR gene expression was identified in 19 out of 21 gonadotroph cell adenomas (90%) and 3 out of 5 null cell adenomas (60%), respectively. However, no significant difference was found in the gene expression for TRHR between gonadotroph cell adenomas and null cell adenomas. It is well known that TRH administration can elicit a rise in the secretion of gonadotropin and/or its' subunits from adenoma cells, a response that is not seen in normal individuals [2, 21, 22] , which may suggest the presence of TRHR in gonadotroph cell adenomas. However, Kim et al. have reported that the responsiveness of plasma gonadotropin to TRH in nonfunctioning pituitary adenomas did not significantly correlate with the levels of TRHR1 mRNA expression [6] . Although the amount of TRHR mRNA expression in each adenoma was not measured in our present study, no definite correlation between not only intact gonadotropin but also the α-subunit response to TRH and TRHR gene expression was confirmed in a large number of our patients. Further studies are therefore needed to clarify the pathophysiological significance of TRHR gene expression in gonadotroph cell adenomas. In addition, a mechanism explaining the abnormal response of gonadotropin and/or subunits to TRH administration in gonadotroph cell adenomas need to be investigated. Moreover, the expression of TRHR itself was not confirmed in this study, however the amount of TRHR expression in pituitary adenomas is expected to be very low, because TRHR PCR bands were very weak in the first PCR and became more prominent following nested PCR in this study.
It has been reported that over expressed TRHR2 in culture cells did not bind to [ 3 H] MeTRH and that response of inter cellular calcium to TRH administration was reduced [5] . Therefore, we expected that TRHR2 would suppress the paradoxical responses to TRH. In our study, there were no pituitary adenomas showing TRHR2 mRNA expression alone, and TRHR2 mRNA was expressed most frequently in nonfunctioning pituitary adenomas (13/27, 48%), followed by TSH cell adenomas (1/3, 33%), prolactinomas (1/8, 13%), and GH cell adenomas (1/23, 4%). However, any definite correlation could not be found between TRHR2 mRNA expression and GH response to TRH in GH cell adenomas, PRL in prolactinomas, or intact gonadotropin and/or a-subunit in nonfunctioning adenomas. Therefore, further studies are necessary to elucidate the role of TRHR2 in pituitary adenomas.
